CDRD has launched a new spin-off company, Sepset Biosciences Inc. Sepset is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier & more targeted treatment of sepsis.
Congrats to Microdermics who won the CDRD Life Sciences Award valued at $10,000 at the 2016 BCIC-New Ventures Competition.
In this photo: Mike Volker, Grant Campany, Jon Jafari
CDRD and the MS Society of Canada have issued a global call for research projects to discover and develop treatments for progressive MS.
By looking at the commonalities in multiple rare diseases rather than just one specific disease, we are moving toward treating the root cause of rare diseases rather than managing the symptoms.
CDRD Expands Global Industry Partnerships with Addition of AstraZeneca!
This private/public partnership will continue to support Canadian health research projects by advancing promising research from the university labs through independent testing and validation and towards clinical trials and commercialization.
Introducing Zucara Therapeutics Inc., a new start-up company created by MaRS Innovation and CDRD.
Zucara is developing a novel drug therapy to reduce the severity and frequency of hypoglycemic (low blood sugar) episodes in people with diabetes.
Quark Venture has made a significant seed investment in Sitka Biopharma – a critical value-creating event that will enable Sitka to advance their lead compound for the treatment of bladder cancer into clinical trials.
Health sciences researchers, entrepreneurs, and companies alike have the opportunity to collaborate with CDRD and thereby access its full suite of expertise, infrastructure, and broad partnerships and networks.
CDRD BY THE NUMBERS:
Headquartered in Vancouver, British Columbia, The Centre for Drug Research and Development (CDRD) is Canada’s national drug development and commercialization engine.
We work in partnership with academia, industry, government and foundations, to provide the specialized expertise and infrastructure to identify and de-risk promising discoveries generated by health-related research, and transform them into commercially viable investment opportunities for the private sector – and ultimately into innovative new therapies for patients.
In doing so, CDRD is actively growing our national health sciences industry into a wholly-optimized generator of economic prosperity for the country.
Since 2008, Canada’s Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR).